



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

SVOPL siRNA (m): sc-153954

BACKGROUND

SVOPL (putative transporter SVOPL), also known as SV2-related protein-like, is a 492 amino acid multi-pass membrane protein belonging to the major facilitator superfamily. SVOPL is a paralog to synaptic vesicle protein (SVOP) that exists as two alternatively spliced isoforms. The gene encoding SVOPL maps to human chromosome 7q34. Chromosome 7 is approximately 158 million bases long, encodes over 1,000 genes and makes up approximately 5% of the human genome. Chromosome 7 has been linked to Osteogenesis imperfecta, Pendred syndrome, Lissencephaly, Citrullinemia and Shwachman-Diamond syndrome. Deletions of portions of the q arm of chromosome 7 are linked to myeloid disorders, including acute myelogenous leukemia and myelodysplasia.

REFERENCES

1. Tsiouras, P., Myers, J.C., Ramirez, F. and Prockop, D.J. 1983. Restriction fragment length polymorphism associated with the pro α 2(I) gene of human type I procollagen. Application to a family with an autosomal dominant form of osteogenesis imperfecta. *J. Clin. Invest.* 72: 1262-1267.
2. Liang, H., Fairman, J., Claxton, D.F., Nowell, P.C., Green, E.D. and Nagarajan, L. 1998. Molecular anatomy of chromosome 7q deletions in myeloid neoplasms: evidence for multiple critical loci. *Proc. Natl. Acad. Sci. USA* 95: 3781-3785.
3. Hillier, L.W., Fulton, R.S., Fulton, L.A., Graves, T.A., Pepin, K.H., Wagner-McPherson, C., Layman, D., Maas, J., Jaeger, S., Walker, R., Wylie, K., Sekhon, M., Becker, M.C., O'Laughlin, M.D., Schaller, M.E., et al. 2003. The DNA sequence of human chromosome 7. *Nature* 424: 157-164.
4. Schoch, C., Kohlmann, A., Dugas, M., Kern, W., Hiddemann, W., Schnittger, S. and Haferlach, T. 2005. Genomic gains and losses influence expression levels of genes located within the affected regions: a study on acute myeloid leukemias with trisomy 8, 11, or 13, monosomy 7, or deletion 5q. *Leukemia* 19: 1224-1228.
5. Eckert, M.A., Galaburda, A.M., Mills, D.L., Bellugi, U., Korenberg, J.R. and Reiss, A.L. 2006. The neurobiology of Williams syndrome: cascading influences of visual system impairment? *Cell. Mol. Life Sci.* 63: 1867-1875.
6. Jacobsson, J.A., Haitina, T., Lindblom, J. and Fredriksson, R. 2007. Identification of six putative human transporters with structural similarity to the drug transporter SLC22 family. *Genomics* 90: 595-609.
7. Leone, G., Pagano, L., Ben-Yehuda, D. and Voso, M.T. 2007. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. *Haematologica* 92: 1389-1398.
8. Yao, J. and Bajjalieh, S.M. 2009. SVOP is a nucleotide binding protein. *PLoS ONE* 4: e5315.
9. Schlessinger, A., Matsson, P., Shima, J.E., Pieper, U., Yee, S.W., Kelly, L., Apeltin, L., Stroud, R.M., Ferrin, T.E., Giacomini, K.M. and Sali, A. 2010. Comparison of human solute carriers. *Protein Sci.* 19: 412-428.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

CHROMOSOMAL LOCATION

Genetic locus: Svopl (mouse) mapping to 6 B1.

PRODUCT

SVOPL siRNA (m) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see SVOPL shRNA Plasmid (m): sc-153954-SH and SVOPL shRNA (m) Lentiviral Particles: sc-153954-V as alternate gene silencing products.

For independent verification of SVOPL (m) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-153954A, sc-153954B and sc-153954C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

SVOPL siRNA (m) is recommended for the inhibition of SVOPL expression in mouse cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor SVOPL gene expression knockdown using RT-PCR Primer: SVOPL (m)-PR: sc-153954-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.